Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 13/20 | 0.51 |
| ▸ | ANPEP | P15144 | 3/20 | 0.36 |
| ▸ | ENPEP | Q07075 | 3/20 | 0.36 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.34 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.33 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4135921 | 0.89 | FOLH1 (0.44) | FOLH1GRM3NAALAD2 | |
| SCHEMBL4143575 | 0.76 | FOLH1 (0.51) | FOLH1ANPEPENPEPCPB2GRM3 | |
| SCHEMBL5483408 | 0.71 | FOLH1 (0.39) | FOLH1CPB2GRM3 | |
| SCHEMBL1278279 | 0.70 | FOLH1 (1.00) | FOLH1ANPEPENPEPCPB2GRM3 | |
| SCHEMBL16529247 | 0.69 | FOLH1 (0.43) | FOLH1GRM3 | |
| SCHEMBL4135915 | 0.64 | FOLH1 (0.44) | FOLH1GRM3NAALAD2 | |
| SCHEMBL20121913 | 0.62 | CPB2 (0.50) | FOLH1CPB2 | |
| SCHEMBL27561990 | 0.62 | FOLH1 (0.46) | FOLH1ANPEPENPEPGRM3NAALAD2 | |
| SCHEMBL108166 | 0.61 | FOLH1 (0.76) | FOLH1GRM3NAALAD2 | |
| SCHEMBL2440247 | 0.61 | FOLH1 (0.71) | FOLH1ENPEPCPB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150079001-A1 | IMAGING AGENTS AND METHODS OF IMAGING NAALADASE OR PSMA | THE JOHNS HOPKINS UNIVERSITY (US) | 2015-03-19 | — | — | US | disclosed |
| US-20120276007-A1 | IMAGING AGENTS AND METHODS OF IMAGING NAALADASE OR PSMA | GEORGETOWN UNIVERSITY (US) | 2012-11-01 | — | — | US | disclosed |
| US-8227634-B2 | Imaging agents and methods of imaging NAALADase or PSMA | POMPER MARTIN GILBERT (US) | 2012-07-24 | — | — | US | disclosed |
| EP-1472541-B1 | IMAGING AGENTS AND METHODS OF IMAGING NAALADASE OF PSMA | UNIV JOHNS HOPKINS (US) | 2009-09-16 | — | — | EP | disclosed |
| US-20090117042-A1 | Imaging agents and methods of imaging NAALADase or PSMA | THE JOHNS HOPKINS UNIVERSITY (US) | 2009-05-07 | — | — | US | disclosed |
| US-7408079-B2 | Imaging prostate cancer | THE JOHNS HOPKINS UNIVERSITY (US) | 2008-08-05 | — | — | US | disclosed |
| EP-1472541-A1 | IMAGING AGENTS AND METHODS OF IMAGING NAALADASE OF PSMA | The Johns Hopkins University (US) | 2004-11-03 | — | — | EP | disclosed |
| US-20040054190-A1 | Imaging prostate cancer | JOHNS HOPKINS UNIVERSITY | 2004-03-18 | — | — | US | disclosed |
| WO-2003060523-A1 | IMAGING AGENTS AND METHODS OF IMAGING NAALADASE OF PSMA | JOHNS HOPKINS UNIVERSITY (US) | 2003-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040054190-A1 | Imaging prostate cancer | FOLH1, DUT, NAALAD2 | FOLH1 1/4885ANPEP 9/4885ENPEP 10/4885 |
| US-20090117042-A1 | Imaging agents and methods of imaging NAALADase or PSMA | FOLH1, DNPEP, NAALAD2 | FOLH1 1/4885ANPEP 6/4885ENPEP 8/4885 |
| US-20150079001-A1 | IMAGING AGENTS AND METHODS OF IMAGING NAALADASE OR PSMA | FOLH1, DNPEP, NAALAD2 | FOLH1 1/4885ANPEP 6/4885ENPEP 8/4885 |
| US-20120276007-A1 | IMAGING AGENTS AND METHODS OF IMAGING NAALADASE OR PSMA | FOLH1, DNPEP, NAALAD2 | FOLH1 1/4885ANPEP 6/4885ENPEP 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.